2. TGF-beta/Smad Epigenetics Immunology/Inflammation Apoptosis Anti-infection
  3. PKC NO Synthase TNF Receptor Parasite
  4. Myricitrin

Myricitrin is a naturally occurring flavonoid, is a nitric oxide (NO) and PKC inhibitor. Myricitrin has central nervous system activity, including anxiolytic-like action. Myricitrin possesses antioxidant, anti-inflammatory, antifibrotic and anti-malarial effects.

For research use only. We do not sell to patients.

Myricitrin Chemical Structure

Myricitrin Chemical Structure

CAS No. : 17912-87-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Myricitrin:

Myricitrin Related Antibodies

Top Publications Citing Use of Products

View All PKC Isoform Specific Products:

View All Isoforms
PKC PKCα PKCβ PKCγ PKCδ PKCε PKCη PKCζ PKCθ PKCμ PKC-ι ℩ PKCι

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Myricitrin is a naturally occurring flavonoid, is a nitric oxide (NO) and PKC inhibitor. Myricitrin has central nervous system activity, including anxiolytic-like action. Myricitrin possesses antioxidant, anti-inflammatory, antifibrotic and anti-malarial effects[1][2][3][4][5].

In Vitro

Myricitrin has strong antioxidant activity as radical scavenger and metal-ion chelator. Myricitrin has been reported to inhibit the aldose reductase activity and the oxidation of low-density lipoprotein, and has anti-malarial effect[1].
Myricitrin exhibits a strong scavenging activity against DPPH and NO radicals, as well as H2O2 (IC50 = 1.31 μg/mL, 21.54 μg/mL and 28.46 μg/mL, respectively)[2].
Raw264.7 cells are pre-treated with Myricitrin (0.2-1 mM) for 2 h and stimulates with LPS (HY-D1056) at a concentration of 100 ng/mL for 4 h. Myricitrin inhibits TNFα production and enhances RANTES (regulated on activation normal T-cell expressed and secreted) production in LPS-stimulated Raw264.7 cells. It should be noted that the inhibitory effect of Myricitrin is not observed when Myricitrin was added either simultaneously or after LPS stimulation[3].
Myricitrin shows proliferation inhibition of Plasmodium falciparum, with IC50 value of 5.4 µg/mL[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Myricitrin Related Antibodies
In Vivo

Myricitrin (10-100 mg/kg; oral gavage; once daily; for two consecutive days) exhibits antioxidant, anti-inflammatory and antifibrotic activity in Carbon tetrachloride (CCl4) (HY-Y0298)-intoxicated mice[2].
Myricitrin (5 -30 mg/kg; i.p.; once) dose-dependently and Olanzapine (HY-14541) blocks the stereotypy and climbing induced by Apomorphine (HY-12723) at doses that does not induce catalepsy[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/cN mice (10-12 weeks old, 23-27 g) following CCl4-intoxication[2]
Dosage: 10, 30 and 100 mg/kg
Administration: Oral gavage; once daily; for two consecutive days
Result: Significantly ameliorated CCl4-induced increase in serum aspartate transaminase (AST) and alanine transaminase (ALT) levels and histopathological changes in the liver.
Hepatic oxidative stress was reduced, as evidenced by the decrease in lipid peroxidation, with concomitant increase in GSH level and CYP2E1 expression.
COX-2 and TNF-α overexpression in the liver was reduced.
The expression of TGF-β1 and α-SMA was markedly ameliorated.
Increased proliferating cell nuclear antigen (PCNA) expression.
Animal Model: Male adult Swiss albino mice (30-40 g)[5]
Dosage: 5 mg/kg, 10 mg/kg, and 30 mg/kg
Administration: i.p.; once
Result: Dose-dependently and Olanzapine (HY-14541) blocked the stereotypy and climbing induced by Apomorphine (HY-12723) at doses.
Molecular Weight

464.38

Formula

C21H20O12
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

O=C1C(O[C@H]2[C@@H]([C@@H]([C@H]([C@H](C)O2)O)O)O)=C(C3=CC(O)=C(O)C(O)=C3)OC4=CC(O)=CC(O)=C14
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (215.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1534 mL 10.7670 mL 21.5341 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.64%

SDS (393 KB)

COA (270 KB) HNMR (293 KB) LCMS (100 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1534 mL 10.7670 mL 21.5341 mL 53.8352 mL
5 mM 0.4307 mL 2.1534 mL 4.3068 mL 10.7670 mL
10 mM 0.2153 mL 1.0767 mL 2.1534 mL 5.3835 mL
15 mM 0.1436 mL 0.7178 mL 1.4356 mL 3.5890 mL
20 mM 0.1077 mL 0.5384 mL 1.0767 mL 2.6918 mL
25 mM 0.0861 mL 0.4307 mL 0.8614 mL 2.1534 mL
30 mM 0.0718 mL 0.3589 mL 0.7178 mL 1.7945 mL
40 mM 0.0538 mL 0.2692 mL 0.5384 mL 1.3459 mL
50 mM 0.0431 mL 0.2153 mL 0.4307 mL 1.0767 mL
60 mM 0.0359 mL 0.1795 mL 0.3589 mL 0.8973 mL
80 mM 0.0269 mL 0.1346 mL 0.2692 mL 0.6729 mL
100 mM 0.0215 mL 0.1077 mL 0.2153 mL 0.5384 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Myricitrin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Myricitrin17912-87-7PKCNO SynthaseTNF ReceptorParasiteProtein kinase CNitric oxide synthasesNOSTumor Necrosis Factor ReceptorTNFRhepatic lipid peroxidationCOX-2TNF-αTGF-β1α-SMAantioxidantanti-inflammatoryantifibroticanti-malarial effectsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Myricitrin
Cat. No.:
HY-N0152
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.